Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery
Latest Information Update: 09 Apr 2024
At a glance
- Drugs Cabiralizumab (Primary) ; HuMax IL8 (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms Spark2
- 04 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.
- 24 May 2021 Status changed from not yet recruiting to recruiting.
- 21 Apr 2021 New trial record